Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief: Results of a double-blind, placebo-controlled clinical trial

Digestion

Volumn 67, Issue 1-2, 2003, Pages 82-89

  Coremans, Georges ^a   Kerstens, René ^b   De Pauw, Martine ^b   Stevens, Marita ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Bowel habit; Colonic transit; Constipation; Enterokinetic; Prucalopride; Selective serotonin receptor agonist

Indexed keywords

PLACEBO; PRUCALOPRIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CARDIOVASCULAR SYSTEM; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DIARRHEA; DISEASE MARKER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; DYSPHAGIA; FECES ANALYSIS; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CENTER; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VERTIGO; VISUAL ANALOG SCALE;

ADULT; BENZOFURANS; CATHARTICS; CHRONIC DISEASE; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SAFETY; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX;

EID: 0037540068     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070202     Document Type: Article

References (37)

1. Sonnenberg A, Koch TR: Epidemiology of constipation in the United States. Dis Colon Rect 1989a;32:1-8.
2. Johanson JF, Sonnenberg A, Koch TR: Clinical epidemiology of chronic constipation. J Clin Gastroenterol 1989;11:525-536.
3. Stewart WF, Liberman JN, Sandler RS, et al: Epidemiology of constipation (EPOC) in the United States: Relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999;94:3530-3540.
4. Drossman DA, Sandler RS, McKee DC, et al: Bowel patterns among subjects not seeking health care: Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 1982;83:529-534.
5. Everhart JE, Go VLW, Johannes RS, et al: A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci 1989;34: 1134-1162.
6. Sonnenberg A, Koch TR: Physician visits in the United States for constipation: In 1958 to 1986. Dig Dis Sci 1989b;34:601-611.
7. Thompson WG, Heaton KW: Functional bowel disorders in apparently healthy people. Gastroenterology 1980;79:283-288.
8. Thompson WG, Creed F, Drossman DA, et al: Functional bowel disorders and chronic functional abdominal pain. Gastroenterol Int 1992; 5:75-91.
9. Thompson WG, Longstreth GF, Drossman DA, et al: Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl II):II43-47.
10. Glia A, Lindberg G: Quality of life in patients with different types of functional constipation. Scand J Gastroenterol 1997;32:1083-1089.
11. Gattuso JM, Kamm M: Review article: The management of constipation in adults. Aliment Pharmacol Ther 1993;7:847-850.
12. Ashraf W, Park F, Lof J, et al: Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther 1995;9:639-647.
13. Badiali D, Corazzini E, Habib FI, et al: Effect of wheat bran in treatment of chronic nonorganic constipation: A double blind controlled trial. Dig Dis Sci 1995;40:349-356.
14. Odes HS, Madar Z: A double blind trial of a celandin, aloevera and psyllium laxative preparation in adult patients with constipation. Digestion 1991;49:65-71.
15. Jones M, Dubois D, Talley N: Laxatives in chronic constipation: A statistical meta-analysis [abstract]. Gastroenterology 1999;116:A67.
16. Briejer MR, Schuurkes JAJ, Sarna SK: Idiopathic constipation: Too few stools and too little knowledge. Trends Pharmacol Sci 1999;20: 1-3.
17. Basotti G, Gaburri M, Imbimbo B, et al: Colonic mass movements in idiopathic chronic constipation. Gut 1988;29:1173-1179.
18. Emmanuel AV, Kamm MA, Roy AJ, et al: Effect of a novel prokinetic drug, RO93877, on gastrointestinal transit in healthy volunteers. Gut 1998;42:511-516.
19. 3 receptors. J Pharmacol Exp Ther 1999;288:93-97.
20. Grider JR, Foxx-Orenstein AE, Jin J-G: 5-Hydroxytryptamine-4 receptor agonists initiate the peristaltic reflex in human, rat and guinea pig intestine. Gastroenterology 1998; 115:370-380.
21. Briejer MR, Meulemans AL, Van Daele P, et al: R093877 induces giant migrating contractions (GMC) and alters colonic motility patterns in awake dogs (abstract). Neurogastroenterol Motil 1998;10:62.
22. Briejer M, Meulemans A, Bosmans J-P, et al: In vitro pharmacology of the novel enterokinetic R093877 (abstract). Gastroenterology 1997; 112:A705.
23. Mannaert E, Van Bortel L, Woestenborghs R, et al: Single-dose and once-daily pharmacokinetics and effects of food on prucalopride in humans (abstract). Gut 1999;45(suppl V):P0252.
24. 4 agonist, prucalopride, in healthy humans. Gut 1999;44:682-686.
25. Cummings JH, Wiggins HS: Transit through the gut measured by analysis of a single stool. Gut 1976;17:219-223.
26. Ghoos Y, Vantrappen G: Clean collection and manipulation of stools. Lancet 1977;i:884-885.
27. Preston DM, Lennard-Jones JE: Severe chronic constipation of young women: 'Idiopathic slow transit constipation'. Gut 1986;27: 41-48.
28. Cleveland MvB, Flavin DP, Ruben RA, Epstein RM, Clark GE: New polyethylene glycol laxative for treatment of constipation in adults. South Med J 2001;94:478-481.
29. Hagger R, Benson M, Lloyd R, et al: A placebo-controlled study to evaluate the effect on colonic transit of R093877 in healthy volunteers (abstract). Gastroenterology 1998;114:A759.
30. Otten MH, Schneider H, Wurzer H, et al: A double-blind, placebo-controlled evaluation of safety and efficacy of 12-week, twice daily treatment with prucalopride in patients with chronic constipation (abstract). Gastroenterology 1999;116:A1055.
31. Van 't Klooster G, De Pauw M, Crabbé R: Tolerability, pharmacokinetics and pharmacodynamics of prucalopride in healthy volunteers (abstract). Gut 1999;45(suppl V):P0264.
32. Poen AC, Felt-Bersma RJF, Meuwissen SGM: A placebo-controlled study to evaluate the effects of repeated oral doses of R093877 on gastrointestinal transit and anorectal manometry in healthy volunteers (abstract). Gastroenterology 1997;112:A807.
33. Vandeplassche G, Crabbé R, De Smedt H, et al: A placebo-controlled study to evaluate the effects of single increasing oral doses of R093877 (R) on bowel habit, safety and tolerability in healthy volunteers (abstract). Gastroenterology 1997;112:A843.
34. Felt-Bersma RJF, Bouchoucha M, Wurzer H, et al: Effects of a new enterokinetic drug, prucalopride, on symptoms of patients with chronic constipation: A double-blind, placebo-controlled, multicenter study in Europe (abstract). Gastroenterology 1999;116:A992.
35. Miner PB Jr, Nichols T, Silvers DR, et al: The efficacy and safety of prucalopride in patients with chronic constipation (abstract). Gastroenterology 1999;116:A1043.
36. 3 receptor. Pharmacol Res 1999;39:375-382.
37. 4 receptor agonist, TS-951, in vitro. Pharmacology 2001;63:8-16.